**Sir,**

We read with interest the article by [@bib3], highlighting as conclusion that *APC*-wild-type (wt) status should be a marker of poor prognosis in microsatellite-stable (MSS) proximal colorectal cancer (CRC). Another important aspect underlined was that proximal *APC*-wt/MSS tumours exhibit features of the sessile serrated pathway, after testing that the prognostic value of the classification according to the *APC* status, and CRC location was reflected at the pathological and molecular level ([@bib3]). They analysed 746 patients, and the median 'age of onset\' of 70 years. Since a few years ago, we are trying to characterise an important subgroup within CRC, as it is early-onset CRC (EOCRC). To date, this subset of CRC appears to be different in comparison with others CRCs with older age of onset, especially those cases showing MSS ([@bib2]; [@bib4]; [@bib5]). We have shown this item, studying EOCRC from clinico-pathological, familial, and molecular points of view, and compared all the features found with a subset of late-onset CRC (LOCRC; diagnosed at an age of 70 years or older; [@bib5]; [@bib1]).

Taking as the starting point the work by [@bib3], we have analysed the same aspects, but applying an age of onset criterion, and compared a total of 56 cases of EOCRC with other 87 LOCRC cases. The methods used to analyze the microsatellite instability status, CpG islands methylator phenotype (CIMP), chromosomal instability by array comparative genomic hybridisation, as well as the clinico-pathological variables described, have been published before ([@bib5]; [@bib1]). *APC* mutation status, as well as the other genes described by [@bib3], have been analysed by next-generation sequencing.

First, the findings shown by [@bib3] according to the prognostic results are confirmed only for LOCRC. In this particular age of onset, among patients with MSS tumours, *APC*-wt proximal cancers showed significantly inferior prognosis for overall survival (OS) and recurrence-free survival (RFS): 30 and 18 months, respectively, for proximal *APC*-wt/MSS tumours compared with proximal *APC*-mutated (mt)/MSS tumours (OS: 56; RFS: 50), and distal-MSS tumours (both ∼40 and 30 months, respectively). Even though, EOCRC subset showed interestingly different results. Worst prognosis subgroup in this age of onset was distal *APC*-mt MSS CRCs, with 55 months of OS and 40 months of RFS. In the progression in relation to a better prognosis, the other distal-MSS CRC group (*APC*-wt) appeared second, being those with the best prognosis, proximal APC-mt MSS cases (OS: 112; RFS: 96).

[@bib3] tested as well that the prognostic value of the classification according to the *APC* status and CRC location was reflected at the pathological and molecular level: first, the poor prognosis *APC*-wt/MSS cancers of the proximal colon consistently showed associations with features of the sessile serrated pathway, including poor differentiation, CIMP-high and *BRAF* mutation, and to a lesser extent mucinous histology and female gender. *APC*-mt/MSS distal cancers displayed the expected classic adenoma--carcinoma pathway features such as *TP53* mutation and high IC, whereas *APC*-mt/MSS proximal cancers showed association with *KRAS* mutation and to a lesser extent with *PIK3CA* mutation, hallmarks of the alternate pathway. *APC*-wt/MSS distal cancers showed no consistently outstanding characteristics, although some tendency towards features of the sessile serrated pathway was noted. Although some of the subsets according to the *APC* mutation status and colon location are not too large in our series (proximal colon subsets), some conclusions should be given according to the differential clinico-pathological and molecular features showed by the *APC* status and colon location classification, when we compared them within the different age-of-onset subgroups. In relation to the EOCRC subgroup, the majority of the characteristics are equivalent for both proximal groups and the *APC*-mt/MSS distal cancers; only *APC*-wt/MSS distal cancers differed, being an important group of sporadic cases without showing any predominant feature of all studied cases. On the other hand, LOCRC fulfilled mostly all the features described by [@bib3], except with regard to the *PIK3CA*-mutation status.

These results not only continue suggesting the different behaviour, in this case in relation to the prognosis, of the MSS-EOCRC cases but also define more accurately one of the groups within the EOCRC whose molecular basis remains unknown, and therefore, for whom a greater effort in its search is necessary: *APC*-wt/MSS distal EOCRC.
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